AZM ( DrugBank: - )
1 disease
| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 228 | Bronchiolitis obliterans | 1 |
228. Bronchiolitis obliterans
Clinical trials : 97 / Drugs : 118 - (DrugBank : 32) / Drug target genes : 33 - Drug target pathways : 156
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT02543073 (ClinicalTrials.gov) | September 2014 | 4/9/2015 | MSC for Treatment of Interstitial Lung Disease After Allo-HSCT | Mesenchymal Stem Cell for Treatment of Interstitial Lung Disease After Allogenetic Hematopoietic Stem Cell Transplantation | Lung Diseases, Interstitial;Hematopoietic Stem Cell Transplantation;Bronchiolitis Obliterans | Biological: MSCs;Drug: AZM;Drug: Glucocorticoid | Nanfang Hospital of Southern Medical University | Sun Yat-sen University | Recruiting | 18 Years | 65 Years | All | 60 | Phase 1/Phase 2 | China |